HomeNewsIndiaThird wave of COVID-19 may hit India in August, peak in September: SBI report
Trending Topics

Third wave of COVID-19 may hit India in August, peak in September: SBI report

Based on historical trends, COVID-19 cases can start rising by the second fortnight of August with peak cases at least a month later, said the SBI Research report

July 06, 2021 / 10:09 IST
Story continues below Advertisement
According to the SBI report, the global data shows that on average, peak COVID-19 cases reached during the third wave are nearly twice or 1.7 times those from the second wave of the pandemic. (Representative image)
According to the SBI report, the global data shows that on average, peak COVID-19 cases reached during the third wave are nearly twice or 1.7 times those from the second wave of the pandemic. (Representative image)

India may see the much-feared third wave of the coronavirus pandemic from the middle of August and the COVID-19 cases would peak in September, said a report by the State Bank of India (SBI) while the country is still fighting with the second wave.

The report, "COVID-19: the race to finishing line," was published by SBI Research on July 5, reported News18.

Story continues below Advertisement

"Going by the current data, India can experience daily COVID-19 cases around 10,000 somewhere around the second week of July. However, the cases can start rising by the second fortnight of August with peak cases at least a month later," SBI’s Group Chief Economic Adviser, Soumya Kanti Ghosh, said in the report.

The report stated that projections are based on "historical trends," while saying that the country reached the peak of the second wave on May 7.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show